AUTHORS

Marie TAUTOU, Charline PERROUIN, Jade RUARD, Léna MARLHOUX, Mélina GAUTHIER, Pierre-Antoine CHOFFOUR, Doriane MATHE, Charles DUMONTET

 

INTRODUCTION

The development of luciferase bioluminescent cell lines have been made by Antineo, a Contrat Research Organisation (CRO) that offers preclinical services and expertise in oncology to accelerate the research programs of private companies and academic institutions. We offer in- vitro and in-vivo models representative of various tumors types (syngeneic or xenograft) including resistance models to standard of care.
Antineo's expertise in oncopharmacology enables a unique accompaniment for an optimal preclinical study design depending on state-of-the art and concurrent compounds in development.
Recently, we have developed new Luciferase bioluminescent (Luc+) cell lines, capable of metabolizing Luciferine.
This new luminescence-based method allows us to track tumors and metastases in in vivo models using our Ivis Imager®.
 

MATERIALS & METHODS

For the development of the luciferase bioluminescent cell lines tumor monitoring, we used SCID CB17 and NSG mice, with the MDA-MB-231 cell line, a model of breast cancer, and DEL cell line, a model of lymphoma.

Compared to the fluorescence method, luminescence is a more sensitive approach allowing whole body imaging and the detection of deep tumors and metastasis in live mice (1).

Antineo-tumor model-luciferase-bioluminescent

RESULTS

Monitoring of a breast cancer line – (MDA-MB-231 Luc+)

• Correlation between tumor volume measured with a caliper and the luciferase bioluminescent signal
• Consistent tumor growth after 2 months of monitoring

Monitoring of a metastasis from a T Lymphoma – (DEL Luc+)

• Detection of a second signal different from the primary tumor, localized under the left paw
• Collection of the lymph node and dissociation of the cells for FACS analysis
• Validation of the second signal resulting of a metastasis from primary tumor

CONCLUSION

We have developed luciferase bioluminescent (Luc+) cell lines by transduction, and we have conducted a first longitudinal follow-up of the MDA-MB-231 cell line (breast cancer), and a second monitoring of the DEL cell line (lymphoma cancer), injected subcutaneously, and the associated metastasis.

The images obtained with the Ivis Imager® allow us to regularly monitor tumors and potential metastases over time and without loss of luminescence.

We also offer alternative experimental designs with the Ivis Imager®:
• Tracking of a luminescent compound to follow its biodistribution
• Orthotopic injection for a more precise and non-invasive follow-up with the classic method (caliper)
• Development of on-demand models

REFERENCES

1. Genevois, Coralie, et al. « In Vivo Follow-up of Brain Tumor Growth via Bioluminescence Imaging and Fluorescence Tomography ». International Journal of Molecular Sciences, vol. 17, no 11, octobre 2016, p. 1815.
2. Liu, Shirley, et al. « Brightening up Biology: Advances in Luciferase Systems for in Vivo Imaging ». ACS Chemical Biology, vol. 16, no 12, décembre 2021, p. 2707‑18.

Contact our Team to learn more

Download the poster here: Poster AFSSI_VF

capture decran 2023 06 05 153508